WHO-GMP sourced EU-GMP partners ISO 9001:2015 49+ export markets Since 2003

Adempas (riociguat) is a soluble guanylate cyclase stimulator for chronic thromboembolic pulmonary hypertension and pulmonary arterial hypertension, taken three times daily as 0.5 mg to 2.5 mg film-coated tablets with dose steps no sooner than 2 weeks apart.

M Care Exports supplies hospitals, licensed importers and tender authorities internationally, with established supply lanes into the GCC, Africa and Europe, including the originator Adempas (riociguat) and Indian-made riociguat tablets. If you are looking for riociguat 0.5 mg, 1 mg or 2.5 mg tablets, send the destination, the strength, the pack and the quantity, and we quote per destination once the registration route and import licence are confirmed.

WhatsApp a riociguat enquiry → Send enquiry by form
WHO-GMP sourcing CDSCO licensed exporter EU-GMP capable partners Cold-chain validated (2–8°C & −25°C) CTD / eCTD dossier-ready ISO 9001:2015
Bulk supply and export terms

Riociguat exporter and bulk supplier from India.

"We need a partner for Adempas" is a typical enquiry from a hospital pharmacy that handles pulmonary hypertension, or from a tender desk. M Care is a merchant-exporter: we supply originator or regulator-registered brands and Indian-made lines, and we confirm which one your destination's registration route accepts before quoting. Adempas tablets come in five strengths (0.5, 1, 1.5, 2 and 2.5 mg) and the label titrates the dose upward in 0.5 mg steps, so one patient can need several strengths during titration. Our roster lists Indian-made riociguat tablets under brand names such as Rioci (0.5 mg and 2.5 mg), Rioteph (1 mg) and Riopah (1 mg). We do not state that any of these is registered in a given destination. The product needs no refrigeration on the US label (25 °C, excursions 15 to 30 °C) or the UK SmPC (no special storage conditions), which keeps freight simple. A related cardiovascular line on our hub is macitentan (Opsumit).

Source

WHO-GMP-certified Indian manufacturing line, named on every quote.

Minimum order

No blanket MOQ. Set by the source manufacturer's minimum batch-release quantity for the strength and pack ordered.

Pricing

On request. Indicative FOB or CIF quote, formal proforma on confirmation.

Incoterms

EXW, FOB, CIF, CIP or DAP.

Payment

Letter of credit (sight or usance) and telegraphic transfer.

Documentation

WHO-GMP certificate of the source line, product-specific CoPP, batch CoA, method of analysis, Free Sale Certificate, Certificate of Origin, CTD or eCTD dossier. On request.

Shelf-life

Minimum remaining shelf-life agreed per order and confirmed on the proforma.

Response

Availability and CoPP status within two working days; pre-alert documents before dispatch.

Request a bulk quote → Send a bulk enquiry by form How bulk supply works
At a glance

Soluble guanylate cyclase (sGC) stimulator, sourced and documented for export.

The EMA page describes riociguat as stimulating the enzyme soluble guanylate cyclase, and the US label calls it a soluble guanylate cyclase (sGC) stimulator. The US label (Bayer HealthCare Pharmaceuticals Inc., DailyMed, revised 8/2026) lists film-coated tablets of 0.5, 1, 1.5, 2 and 2.5 mg, for adults with persistent or recurrent chronic thromboembolic pulmonary hypertension (CTEPH, WHO Group 4) after surgery or with inoperable CTEPH, and for adults with pulmonary arterial hypertension (PAH, WHO Group 1). The US label gives a starting dose of 1 mg three times a day, with 0.5 mg three times a day considered where hypotension may not be tolerated. The dose rises by 0.5 mg three times a day no sooner than 2 weeks apart if systolic blood pressure stays above 95 mmHg without signs of hypotension, to a maximum of 2.5 mg three times a day. The EMA page lists Bayer AG as marketing authorisation holder, with the marketing authorisation issued on 27 March 2014. The EMA page and the UK SmPC also cover PAH in paediatric patients (the UK SmPC states aged 6 to under 18 years) in combination with endothelin receptor antagonists, whereas the US label states that safety and effectiveness in paediatric patients have not been established. The EMA page adds that, for children weighing below 50 kg, Adempas is also available as granules made up into a liquid taken by mouth. The UK SmPC lists pack sizes of 42, 84, 90 or 294 tablets in PP/aluminium foil blisters, not all of which may be marketed.

Active ingredient

Riociguat. Soluble guanylate cyclase (sGC) stimulator.

Forms and strengths

0.5 mg film-coated tablet; 1 mg film-coated tablet; 1.5 mg film-coated tablet; 2 mg film-coated tablet; 2.5 mg film-coated tablet.

Indications

Riociguat is a soluble guanylate cyclase stimulator used for chronic thromboembolic pulmonary hypertension (CTEPH) and pulmonary arterial hypertension (PAH), supplied as film-coated tablets in five strengths.

Administration

Oral. Film-coated tablet.

Documentation

Batch-specific CoA, CoPP, manufacturing-site WHO-GMP certificate and stability data compiled per consignment, in the format the destination regulator expects.

Who we supply

Hospital pharmacies, licensed importers and tender desks across our export markets.

India is our origin. We do not sell into the Indian market.

Buyers are hospital pharmacists in cardiology and pulmonary hypertension units, MoH and hospital tender desks, and licensed importers and distributors internationally. Typical enquiries read "I'm looking for riociguat 1 mg tablets for a hospital formulary" or "We need a partner for Adempas 2.5 mg for a tender". Each destination has its own route to registration or import, for example the Emirates Drug Establishment (EDE) in the UAE, NAFDAC in Nigeria and the MHRA in the UK, and we align the offer with it before quoting. The UK SmPC states that treatment should only be initiated and monitored by a physician experienced in the treatment of CTEPH or PAH. Whether a destination needs a registered product or a named-patient or unlicensed import depends on the destination regulator, and M Care Exports confirms the route per enquiry. M Care supplies both originator or regulator-registered brands and Indian-made lines.

GCC registration routes

Supply against MoH registration held by your local licensed importer, or via the GCC central registration pathway.

MoH registration, GCC →

UK unlicensed routes

Where no UK licence exists, the MHRA Specials and named-patient import routes cover clinically justified demand.

MHRA Specials →

Tender desks

Bid-pack documentation assembled to the tender's specification, from CoPP to batch records.

Tender response →

Dossier support

CTD documentation from the sourcing manufacturer, compiled for your regulator's format.

Dossier preparation →

Pharmacist's note

What the dispensing pharmacist checks on riociguat.

Plan the pack list around titration, because one patient moves through several strengths. The US label starts at 1 mg three times a day, or 0.5 mg where hypotension may not be tolerated, then adds 0.5 mg three times a day no sooner than 2 weeks apart if systolic blood pressure stays above 95 mmHg without signs of hypotension, to a maximum of 2.5 mg. The UK SmPC gives the same 2-week step and spaces doses approximately 6 to 8 hours apart. The US label says to re-titrate if treatment is interrupted for 3 days or more, and allows crushed tablets mixed with water or soft food. The US label reports plasma concentrations reduced by 50% to 60% in smokers and lets prescribers consider doses above 2.5 mg three times a day in smokers if tolerated; the UK SmPC advises current smokers to stop. US contraindications include pregnancy (boxed warning, with contraception before, during and for one month after treatment), nitrates or nitric oxide donors, PDE inhibitors and other sGC stimulators. The UK SmPC also contraindicates severe hepatic impairment (Child-Pugh C). Storage is 25 °C on the US label (excursions 15 to 30 °C) and no special conditions on the UK SmPC, which gives a 5-year shelf life.

Regulatory & quality

The documentation pack a regulator actually asks for.

Riociguat tablets are an ambient-temperature product on the texts we read, so no cold chain applies. The US label gives 25 °C with excursions permitted from 15 to 30 °C, and the UK SmPC states that the product does not require any special storage conditions, with a shelf life of 5 years. The EMA page lists Adempas as authorised in the EU under Bayer AG. A separate EMA page shows that on 23 July 2026 the CHMP adopted a positive opinion recommending a marketing authorisation for Riociguat Accord (applicant Accord Healthcare S.L.U.), a generic of Adempas, and that page still shows the medicine at opinion stage. In the US, Drugs@FDA lists an approved generic riociguat tablet under ANDA 211135 (company MSN) in all five strengths, with a therapeutic equivalence code of AB against Adempas. The UK emc search for riociguat returns only Adempas in five strengths. M Care documentation covers batch certificates of analysis, export documents and destination-aligned dossier support where the regulator asks for it. We state the source and status of each line before quoting, and make no manufacturing or WHO claim for M Care itself.

CoA and MoA, per batch

Batch-specific certificate and method of analysis from the sourcing manufacturer's QC release.

CoPP, WHO-GMP, MFG licence

Certificate of pharmaceutical product, site GMP certificate and manufacturing licence, issued by the state drug regulator and naming the actual manufacturing site.

CTD Module 3

Chemistry, manufacturing and controls documentation available from the sourcing manufacturer for registration filings.

Pack insert, labels, artwork

Destination-language patient information and labelling to the local regulator's standard, locked before shipment.

Pharmacovigilance

A named PV contact arranged in the destination market where the registration requires one.

How the enquiry works

Molecule · strength · volume · destination. One working day to a quote.

  1. Send us the specifics. Form and strength, pack preference, destination market and indicative volume for riociguat.
  2. We route to the right line. The enquiry goes to the WHO-GMP certified manufacturing partner whose certificates fit your regulator.
  3. Commercial and regulatory offer. FOB or CIF price with the documentation list, named manufacturing site and current certificate validity.
  4. Order, produce, release, ship. QC release on the Indian side, batch documents compiled, despatch on the agreed incoterm.
  5. After delivery. Batch records and certificates archived and retrievable for the life of the product on your shelf.
Frequently asked

Riociguat supply, the specific questions.

What is the Adempas cost for an importer?

We do not publish prices. The landed cost of Adempas depends on whether you want the originator brand or an Indian-made riociguat line, the strength (0.5, 1, 1.5, 2 or 2.5 mg), the pack size, the quantity, the registration route in your destination and the Incoterms. No cold chain applies on the US label or the UK SmPC, so freight is simpler than for refrigerated products. M Care Exports quotes per destination once we have the strength, pack and quantity.

Is there an Adempas generic?

It depends on the market. In the US, Drugs@FDA lists an approved generic riociguat tablet under ANDA 211135 (company MSN) in 0.5, 1, 1.5, 2 and 2.5 mg, with a therapeutic equivalence code of AB against Adempas. In the EU, the CHMP adopted a positive opinion on 23 July 2026 recommending authorisation of Riociguat Accord, a generic of Adempas, and the EMA page still shows it at opinion stage. The UK emc search for riociguat returns only Adempas. Other destinations register on their own rules, and M Care Exports confirms what your regulator accepts before we quote.

I'm looking for an alternative to the Adempas brand. What do you supply?

M Care supplies both originator or regulator-registered brands and Indian-made lines. Our roster lists Indian-made riociguat tablets such as Rioci (0.5 mg and 2.5 mg), Rioteph (1 mg) and Riopah (1 mg). We do not describe these as generics or biosimilars, and we do not claim they are registered in any destination. Whether your regulator accepts an Indian-made line, or only a registered product, is confirmed per enquiry.

What is Adempas used for?

The US label lists two indications in adults: persistent or recurrent CTEPH after surgical treatment or inoperable CTEPH (WHO Group 4), and PAH (WHO Group 1). The EU and UK texts cover the same two conditions for adults at WHO Functional Class II to III, and add PAH in paediatric patients in combination with endothelin receptor antagonists (the UK SmPC states aged 6 to under 18 years). The US label says paediatric safety and effectiveness have not been established. Indications vary by destination labelling.

How is Adempas dosed, and which strengths do I need to stock?

The US label starts at 1 mg three times a day, or 0.5 mg three times a day where hypotension may not be tolerated. The dose rises by 0.5 mg three times a day no sooner than 2 weeks apart, if systolic blood pressure stays above 95 mmHg without signs of hypotension, to a maximum of 2.5 mg three times a day. Because patients step through strengths, a hospital may need 0.5, 1, 1.5, 2 and 2.5 mg tablets in stock. Prescribers decide the regimen.

Does Adempas need a cold chain?

No. The US label gives storage at 25 °C with excursions permitted from 15 to 30 °C, and the UK SmPC states that the product does not require any special storage conditions, with a shelf life of 5 years. Always confirm the storage text of the specific pack and market you are importing. The UK SmPC lists pack sizes of 42, 84, 90 or 294 tablets in PP/aluminium foil blisters, not all of which may be marketed.

Sources and review

Who stands behind this page, and where its statements come from.

Reviewed by Dr. Rajat Bhatt, PharmD, Managing Director, M Care Exports. Last reviewed 2026-11-15.

This page is sourcing information for licensed importers, hospital procurement and tender desks. It is not medical, pharmaceutical or prescribing advice, and it is not a substitute for the approved product information of the line on your order. See our full disclaimer.

Riociguat enquiry

Send the specifics. You'll have a price inside one working day.

Form and strength, destination market and indicative volume. The Mumbai desk replies within one working day, including when the honest answer is that the route is not viable yet.

WhatsApp the Mumbai desk → Enquiry form Back to cardiovascular